EcoDrugPlus

Checkpoint Kinase 2

Ensembl ID : ENSBTAG00000004956
Gene Symbol: CHEK2
23 Enzyme and pathways 5 Cross references
218 Possible Orthologues:

Chemokine (C-C Motif) Receptor 1

Ensembl ID : ENSBTAG00000019428
Gene Symbol: CCR1
8 Enzyme and pathways 4 Cross references
163 Possible Orthologues:

Chemokine (C-X-C Motif) Receptor 1

Ensembl ID : ENSBTAG00000026753
Gene Symbol: CXCR1
11 Enzyme and pathways 4 Cross references
288 Possible Orthologues:

Cholecystokinin A Receptor

Ensembl ID : ENSBTAG00000004988
Gene Symbol: CCKAR
7 Enzyme and pathways 5 Cross references
213 Possible Orthologues:

Cholinergic Receptor Muscarinic 1

Ensembl ID : ENSBTAG00000011579
Gene Symbol: CHRM1
8 Enzyme and pathways 5 Cross references
116 Possible Orthologues:

Cholinergic Receptor Muscarinic 2

Ensembl ID : ENSBTAG00000014674
Gene Symbol: CHRM2
12 Enzyme and pathways 5 Cross references
273 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSBTAG00000008059
Gene Symbol: CHRM3
8 Enzyme and pathways 3 Cross references
269 Possible Orthologues:

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSBTAG00000033699
Gene Symbol: CHRM4
5 Cross references
197 Possible Orthologues:

Cholinergic Receptor Muscarinic 5

Ensembl ID : ENSBTAG00000037985
Gene Symbol: CHRM5
8 Enzyme and pathways 5 Cross references
276 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSBTAG00000003130
Gene Symbol: CHRNA3
9 Enzyme and pathways 5 Cross references
214 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 4 Subunit

Ensembl ID : ENSBTAG00000017198
Gene Symbol: CHRNA4
9 Enzyme and pathways 5 Cross references
216 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSBTAG00000007517
Gene Symbol: CHRNB2
9 Enzyme and pathways 5 Cross references
210 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).